BridgeMD
New treatment option for Mild Stroke
Official title Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
ClinicalTrials.gov ID: NCT07095790
What this study is testing
What is Tirofiban+Oral Dual Antiplatelet Therapy?
Tirofiban+Oral Dual Antiplatelet Therapy is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for mild stroke.
Also referred to as Tirofiban with Sequential Dual Antiplatelet Therapy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age: 18-80 years old.
- Acute mild non-cardioembolic stroke.
- NIHSS score ≤5.
- Time from onset to randomization of ≤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ≤48...
- The investigational drug can be administered within 48 hours of symptom onset.
You likely can't join if
- Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)
- Intracranial hemorrhage confirmed by imaging.
- Pre-stroke modified Rankin Scale (mRS) score ≥2.
- Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart...
- History of primary intracerebral hemorrhage.
- History of other intracranial hemorrhage (intraventricular, subarachnoid, epidural, or subdural hemorrhage).
See the full eligibility criteria
- Age: 18-80 years old.
- Acute mild non-cardioembolic stroke.
- NIHSS score ≤5.
- Time from onset to randomization of ≤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ≤48 hours.
- The investigational drug can be administered within 48 hours of symptom onset.
- Signed informed consent by the patient or legally authorized representative.
- Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)
- Intracranial hemorrhage confirmed by imaging.
- Pre-stroke modified Rankin Scale (mRS) score ≥2.
- Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus or vegetation...
- History of primary intracerebral hemorrhage.
- History of other intracranial hemorrhage (intraventricular, subarachnoid, epidural, or subdural hemorrhage).
- Untreated or inadequately treated intracranial aneurysm or vascular malformation.
- Major systemic bleeding within 30 days.
- Active bleeding, including laboratory evidence of coagulopathy (platelet count \ 50 seconds, or international normalized ratio \>1.7), or treatment with direct oral anticoagulants within the preceding 48 hours.
- Major surgery within 14 days.
- Persistently elevated blood pressure (systolic \>180 mmHg or diastolic \>110 mmHg) despite treatment.
- Baseline platelet count \<100 × 10⁹/L.
- Severe renal dysfunction (glomerular filtration rate \ 220 μmol/L [2.5 mg/dL]).
- Known allergy or contraindication to tirofiban or aspirin.
- Current pregnancy or lactation.
- Any intracranial tumor (except asymptomatic meningiomas ≤1.5 cm in diameter).
- Any terminal illness with life expectancy \<6 months.
The study team makes the final eligibility decision.
Where it's taking place
- Suzhou, Anhui, China
- Shijiazhuang, Hebei, China
- Zhoukou, Henan, China
- Bayan Nur, Inner Mongolia, China
- Huai'an, Jiangsu, China
- Suqian, Jiangsu, China
- Suzhou, Jiangsu, China
- Taizhou, Jiangsu, China
- Xi'an, Shaanxi, China
- Xianyang, Shaanxi, China
- Tianjin, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Suzhou, Anhui, China; Shijiazhuang, Hebei, China; Zhoukou, Henan, China; Bayan Nur, Inner Mongolia, China; Huai'an, Jiangsu, China; Suqian, Jiangsu, China and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.